Austin, TX – According to filings with the U.S. Securities and Exchange Commission, Lung Therapeutics is raising $15,000,000.00 in new funding. Sources indicate as part of senior management President, Brian Windsor played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lung Therapeutics

Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The companys lead drug candidate, LTI-01, is in clinical development for Loculated Pleural Effusion (LPE) and has successfully completed a clinical trial in LPE patients. The companys second drug candidate, LTI-03, is in clinical development for Idiopathic Pulmonary Fibrosis (IPF).

To learn more about Lung Therapeutics, visit http://lungtx.com/

Contact:
Brian Windsor, President
737-802-1989
bwindsor@lungtx.com
https://www.linkedin.com/in/windsorbrian/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved